Hinova Pharmaceuticals (SH:688302) Ge Long Hui·2026-02-01 09:04Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has received approval from the Sichuan Provincial Drug Administration for its GMP compliance inspection, allowing the company to expand its production capabilities in the oncology drug sector [1] Group 1: Regulatory Approval - The company has been issued a GMP compliance inspection notice (No. 川许2026035) confirming that its soft capsule production line for the oncology drug Deutetrabenazine meets the required standards [1] - Following the inspection, the company has completed the necessary changes to its Drug Production License [1] Group 2: License Changes - The changes to the Drug Production License include a new registered address located at 558 Phoenix Road, Shuangliu District, Chengdu, Sichuan Province [1] - The production scope has been expanded to include soft capsules for oncology drugs, with the classification code changing from "Bh" to "AhBh" [1]